GENEMAP OF THE HUMAN GENES ASSOCIATED WITH SCHIZOPHRENIA

The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SEGAL, JONATHAN, KEITH, TIM, DUBOIS, DANIEL, CROTEAU, PASCAL, PAQUIN, NOUZHA, BELOUCHI, ABDELMAJID, PAQUIN, BRUNO, FOURNIER, HELENE, RAELSON, JOHN VERNER, BRADLEY, WALTER EDWARD, VAN EERDEWEGH, PAUL, LITTLE, RANDALL, DAVID, BRUAT, VANESSA
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to SCHIZOPHRENIA disease and/or their response to a particular drug or drugs. Cette invention concerne la sélection d'un ensemble de marqueurs de polymorphisme utilisables dans les études d'association sur le génome entier reposant sur la cartographie des déséquilibres de liaison. En particulier, l'invention concerne les domaines de la pharmacogénomique, du diagnostic, du traitement thérapeutique, et l'utilisation des données concernant les haplotypes génétiques pour prédire la sensibilité d'un sujet à la schizophrénie et/ou sa réponse à un/des médicament(s) donné(s).